# Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

> **NCT02686008** · PHASE1 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02686008
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was stopped due to lack of funding.
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02686008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02686008, "Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02686008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*